How to Fight Insurance Denials for Chronic Wound Care Treatment

Chronic wounds—diabetic foot ulcers, venous leg ulcers, pressure injuries, and surgical wounds that won't heal—affect millions of Americans and can lead to infection, amputation, and death if undertreated. When standard care (debridement, dressings, offloading) fails after four to six weeks, evidence supports advanced therapies like hyperbaric oxygen (HBOT), negative-pressure wound therapy (NPWT or "wound vac"), and bioengineered skin substitutes (Apligraf, Dermagraft, EpiFix, Grafix). Yet insurers deny these treatments at high rates, citing "experimental," "not medically necessary," or "criteria not met" even when the medical record supports coverage. This guide walks you through the most common denial templates, the specific clinical guidelines and policy citations that carry weight, and how to structure an effective appeal.

Why Insurers Deny Chronic Wound Care

Insurers use several recurring templates to deny advanced wound therapies, even when clinically appropriate:

1. "Standard care has not been tried for an adequate duration."

The insurer claims you haven't exhausted basic wound care—debridement, moisture-retentive dressings, offloading, compression—for the required four to six weeks. Often the medical record does document standard care but uses vague language ("ongoing wound care") instead of specific CPT codes, dates, and wound measurements showing lack of healing.

2. "The wound does not meet severity or chronicity criteria."

For HBOT, insurers require Wagner Grade 3 or higher diabetic foot ulcers with documented osteomyelitis or deep abscess, plus failure of at least 30 days of standard care (CMS NCD 20.29). For skin substitutes, Medicare LCDs require wounds present for at least four weeks with less than 50% area reduction despite standard care. If your chart lacks serial measurements or understates severity, the insurer can claim the wound is "too mild."

3. "Vascular workup is incomplete or the wound is non-healing due to ischemia."

Advanced wound products won't heal ischemic tissue. Most policies require documentation of adequate perfusion: ankle-brachial index (ABI) ≥0.8 for venous ulcers, transcutaneous oxygen pressure (TcPO₂) measurements for HBOT candidacy, or duplex ultrasound showing arterial inflow and venous reflux patterns. If the chart is silent on vascular status or shows severe PAD without a revascularization plan, insurers deny as "futile."

4. "The requested therapy is experimental / investigational / unproven."

This is common for newer cellular or tissue-based products (CTPs) like dehydrated human amnion-chorion membrane (EpiFix) and cryopreserved placental grafts (Grafix). Insurers claim insufficient randomized trial data, even though Medicare and most commercial plans have published Local Coverage Determinations (LCDs) explicitly covering these products with HCPCS codes (Q4186, Q4133, Q4101, Q4106).

5. "The treatment is not covered under your plan / excluded benefit."

Some Medicare Advantage and Medicaid managed-care plans exclude HBOT or limit skin substitutes to one or two applications despite FDA clearance and CMS coverage. This is a contractual exclusion rather than a medical necessity denial and requires a different appeal strategy (often external review or state fair hearing).

The Citations Insurers Respect

When you appeal, reference the specific policies, guidelines, and trials that underpin standard of care. Payers cannot ignore their own coverage determinations or consensus statements from national wound societies. Below are the key documents—use the exact titles and years:

CMS National Coverage Determination (NCD) 20.29 — Covers HBOT for Wagner Grade 3+ diabetic foot ulcers with at least 30 days of failed standard wound therapy. This is binding on all Medicare Advantage plans.

CMS Local Coverage Determination (LCD) L33821 — Covers negative-pressure wound therapy (NPWT) for Stage 3–4 pressure injuries, dehisced surgical wounds, and chronic diabetic or venous ulcers. Updated policy specifies wound bed preparation, adequate perfusion, and weekly re-evaluation.

CMS LCD L35041 (Novitas and other MACs) — Covers cellular and tissue-based products (CTPs) including Apligraf (Q4101), Dermagraft (Q4106), EpiFix (Q4186), and Grafix (Q4133) for diabetic foot ulcers and venous leg ulcers when wounds persist ≥4 weeks with <50% area reduction under standard care. Requires documentation of adequate perfusion (ABI ≥0.7 or TcPO₂ ≥30 mmHg), offloading for DFUs, and compression for VLUs.

Society for Vascular Surgery (SVS) 2016 Diabetic Foot Guidelines — Multi-society consensus (SVS, American Podiatric Medical Association, Society for Vascular Medicine) defining the "4-week rule": wounds showing <50% area reduction after four weeks of standard care are unlikely to heal without advanced intervention. Cited widely in LCD rationales.

Undersea and Hyperbaric Medical Society (UHMS) 14th Edition Indications — Lists Wagner Grade 3+ diabetic lower-extremity wounds as an approved HBOT indication. Requires documented standard care failure, adequate glycemic control attempt, vascular evaluation, and infection control.

International Working Group on the Diabetic Foot (IWGDF) / Infectious Diseases Society of America (IDSA) 2023 Guidelines — Define diabetic foot infection (DFI) severity, osteomyelitis workup (probe-to-bone, MRI), and systemic antibiotic selection. Useful when insurers deny IV antibiotics or long-duration oral regimens for bone infection.

Wound Healing Society (WHS) 2022 Update on Chronic Wound Management — Recommends sharp debridement, offloading with total contact casting (TCC), multilayer compression for venous ulcers, and adjunctive NPWT or CTPs when standard care plateaus.

National Pressure Injury Advisory Panel (NPIAP) 2016/2019 Staging System — Defines Stage 3 (full-thickness skin loss), Stage 4 (exposed bone/tendon), unstageable (eschar-covered), and deep tissue injury. Medicare LCDs for NPWT and support surfaces reference these definitions.

When an insurer cites an outdated or internal policy, respond by pointing to these public, peer-reviewed standards. If a commercial plan's medical policy contradicts CMS LCDs or national guidelines, note the discrepancy explicitly in your appeal letter—many state insurance regulators require payers to follow "generally accepted standards of medical practice."

How to Argue Against "Standard Care Not Tried Long Enough"

Step 1: Construct a timeline table.

List every wound-related encounter from initial presentation through the current denial. Columns: Date | Provider | Procedure (CPT code) | Wound Measurement (L × W × D cm, area cm²) | % Change | Notes (offloading device, dressing type).

Step 2: Highlight the 4-to-6-week threshold.

Draw a box around the period meeting SVS 2016 criteria (≥4 weeks, <50% area reduction). Example: "From 2026-01-15 to 2026-02-26 (6 weeks), patient received six sessions of sharp debridement (CPT 11042), daily calcium alginate dressings, and offloading walker. Initial area 6.2 cm², week-4 area 5.8 cm² (6% reduction). Per SVS 2016, <50% reduction predicts non-healing without advanced therapy."

Step 3: Cite procedure codes and dates, not vague notes.

Replace "patient has had wound care" with "CPT 97597 × 4 sessions (dates), CPT 11042 × 3 sessions (dates), total contact cast applied 2026-02-27 (CPT 29445)." Vague documentation is the #1 reason for "insufficient trial" denials.

Step 4: Document why the patient couldn't tolerate or failed each standard modality.

If offloading failed because the patient couldn't ambulate in a cast boot, state that and note the upgrade to total contact cast. If enzymatic debridement was tried but caused maceration, include the wound photos. Insurers assume non-compliance; show you've addressed barriers.

Step 5: Attach the SVS 2016 guideline excerpt and your LCD.

Include a one-page PDF of the relevant section. Write: "Our treatment course exceeds the standard-care duration defined in SVS 2016 (attached) and meets the chronicity requirement of LCD L35041 for CTP coverage."

How to Argue Against "Severity or Chronicity Criteria Not Met"

Step 1: Use the staging/grading system the LCD requires.

For diabetic foot ulcers, cite Wagner grade (0–5) and note depth: "Wagner Grade 3—full-thickness ulcer with abscess, probe-to-bone test positive on 2026-03-10, MRI confirms 1st metatarsal osteomyelitis." For pressure injuries, use NPIAP staging: "Stage 4 sacral pressure injury, 4.5 × 3.8 cm, exposed coccyx, undermining 1.2 cm at 6-o'clock." For venous ulcers, note CEAP classification: "CEAP C6 (active venous ulcer) with saphenofemoral reflux >3 sec on duplex."

Step 2: Provide serial wound measurements and photos.

A single measurement isn't enough. Show the wound at baseline, week 2, week 4, and current. Calculate area in cm² and percentage change. Example: "Week 0: 8.0 cm². Week 4: 7.5 cm² (6% reduction). Week 8: 7.2 cm² (10% total reduction). Wound has plateaued below the 50% healing threshold."

Step 3: Document infection or osteomyelitis.

For HBOT (NCD 20.29), Wagner Grade 3+ requires either deep abscess or bone involvement. Include the probe-to-bone result ("positive at base, bone gritty"), ESR/CRP (elevated >30/10), and MRI report ("marrow edema and cortical destruction of distal first metatarsal, consistent with osteomyelitis"). If you had a bone biopsy, attach the pathology. Insurers cannot deny HBOT when osteomyelitis is documented and standard care has failed.

Step 4: Show why the wound is "chronic."

Most LCDs define chronic as ≥4 weeks. State: "This ulcer has been continuously present since 2026-01-15 (14 weeks at time of request), meeting the chronicity threshold of LCD L35041."

Step 5: Rebut "too mild" claims with guideline language.

If the insurer says "This is only a Wagner 2, not severe enough for HBOT," respond: "While the ulcer was Wagner 2 at presentation, it progressed to Wagner 3 with confirmed osteomyelitis by week 6 (MRI 2026-03-10), meeting NCD 20.29 criteria."

How to Argue Against "Incomplete Vascular Workup" or "Ischemia"

Step 1: Provide ABI, TBI, and TcPO₂ with dates and interpretation.

Example: "ABI right lower extremity 0.78 (mild PAD, above the 0.7 threshold for CTP use per LCD L35041). Toe-brachial index 0.42 (moderate ischemia). TcPO₂ right foot dorsum 28 mmHg at room air, 52 mmHg on 100% O₂ challenge (UHMS criteria: >10 mmHg rise suggests HBOT will improve tissue oxygenation)."

Step 2: Show a revascularization plan if PAD is present.

Insurers correctly deny wound therapies when severe ischemia (ABI <0.5, TcPO₂ <30 without O₂ response) goes untreated. Include the vascular surgery consult note: "CTA 2026-03-12 shows 70% right SFA stenosis. Endovascular intervention scheduled 2026-04-15. Vascular surgery recommends HBOT adjunctively post-revascularization per UHMS guidelines."

Step 3: For venous ulcers, document reflux and compression.

LCD L35041 requires duplex showing venous insufficiency (reflux >0.5 sec superficial, >1.0 sec deep) and trial of compression therapy if ABI ≥0.8. Example: "Duplex 2026-02-20: greater saphenous vein reflux 2.4 sec. ABI 0.92. Patient has worn multilayer compression (Profore) for 6 weeks; ulcer area decreased only 8%."

Step 4: Cite UHMS oxygen-challenge protocol for HBOT.

If denied for "inadequate perfusion," respond: "UHMS 14th Edition specifies TcPO₂ with 100% O₂ challenge to identify HBOT responders. Our patient's 24 mmHg increase (28→52 mmHg) demonstrates recruitable perfusion, predicting HBOT benefit."

Step 5: Attach imaging and vascular reports.

Don't summarize—include the actual duplex, CTA, or MRA report and the vascular surgeon's letter. This removes ambiguity.

How to Argue Against "Experimental / Investigational" for Skin Substitutes

Step 1: Cite the HCPCS code and LCD by name.

"Apligraf (HCPCS Q4101) is explicitly covered under CMS LCD L35041 for diabetic foot ulcers and venous leg ulcers meeting chronicity and standard-care-failure criteria. This is not investigational; it is an FDA-cleared device with a designated reimbursement code."

Step 2: List the pivotal trials.

For Apligraf: Veves et al. Diabetes Care 2001 (56% closure at 12 weeks vs. 38% control). For Dermagraft: Marston et al. Diabetes Care 2003 (30% closure at 12 weeks vs. 18%). For dehydrated amnion-chorion (EpiFix): Zelen et al. Int Wound J 2013 and 2015 (RCTs in DFU and VLU). Note: "These are peer-reviewed, prospective RCTs published in Diabetes Care and other high-impact journals, not case reports."

Step 3: Highlight that CMS and FDA have approved the product.

"FDA regulates CTPs under Section 361 (human cells/tissues) or granted PMA/510(k) clearance. CMS publishes HCPCS codes and payment rates, confirming these are established, not experimental, therapies. Denial as 'investigational' contradicts CMS policy."

Step 4: Compare to your plan's own medical policy.

If you have commercial insurance, request the plan's wound-care medical policy. Many mirror Medicare LCDs. If the policy lists your product as covered, quote the policy number and effective date. If silent, cite the LCD and note "Your policy does not exclude CTPs; national standard is coverage per LCD L35041."

Step 5: Note the consequences of delay.

"Each week of delay increases infection risk, hospitalization, and amputation likelihood. American Diabetes Association 2023 standards emphasize early escalation to advanced therapy when standard care plateaus. Denial exposes the patient to preventable morbidity."

How to Argue Against "Not a Covered Benefit" / Plan Exclusions

Step 1: Distinguish medical necessity from contract exclusion.

If the denial letter says "HBOT is excluded under your plan," this is not a medical necessity denial—it's a contractual limitation. Your appeal strategy differs.

Step 2: Request the Summary Plan Description (SPD) or Evidence of Coverage (EOC).

Ask for the section listing exclusions. If wound care or HBOT is not listed, the exclusion is invalid. Write: "The SPD does not list hyperbaric oxygen as an excluded service. Under ERISA §502, the plan must cover medically necessary services not explicitly excluded."

Step 3: Check state mandates (for fully insured plans).

Some states mandate coverage for diabetic supplies, wound care, or limb-preservation services. If your plan is state-regulated (not self-funded ERISA), cite the statute. Example: "California Health and Safety Code §1367.005 requires coverage of medically necessary diabetes treatment to prevent complications."

Step 4: File for external review or state fair hearing.

Federal law (Affordable Care Act §2719) and many state laws guarantee external review of medical necessity denials. If the denial is based on contract exclusion and you've exhausted internal appeals, request external review by an independent physician reviewer. For Medicaid, request a state fair hearing within 30–90 days.

Step 5: Argue that exclusion is arbitrary when CMS covers the service.

"Medicare NCD 20.29 covers HBOT for diabetic foot osteomyelitis. Excluding this service for a Medicare Advantage enrollee, when Original Medicare covers it, violates the requirement that MA plans provide benefits at least as generous as Medicare (42 CFR §422.100)."

What We Do

We help patients, families, and advocates navigate insurance denials for medically necessary wound care. We analyze denial letters, gather the clinical documentation and policy citations that carry weight, and draft detailed appeal letters grounded in CMS coverage determinations, national guidelines, and peer-reviewed evidence. We coordinate with your wound care team to ensure the medical record includes the specific data points—Wagner grade, wound measurements, vascular studies, standard-care timelines—that turn denials into approvals. If you've been denied HBOT, a wound vac, Apligraf, or another advanced therapy, we can help you build a winning appeal.

Sources

1. Centers for Medicare & Medicaid Services. National Coverage Determination (NCD) 20.29: Hyperbaric Oxygen Therapy. Revised 2017.

2. Centers for Medicare & Medicaid Services. Local Coverage Determination (LCD) L33821: Negative Pressure Wound Therapy. Novitas Solutions, CGS, Palmetto GBA (multiple MACs). Updated 2022–2023.

3. Centers for Medicare & Medicaid Services. Local Coverage Determination (LCD) L35041: Skin Substitute Application. Novitas Solutions (J-L). Updated 2021–2024.

4. Hingorani A, et al. The management of diabetic foot: A clinical practice guideline by the Society for Vascular Surgery in collaboration with the American Podiatric Medical Association and the Society for Vascular Medicine. J Vasc Surg. 2016;63(2 Suppl):3S-21S. (SVS 2016)

5. Undersea and Hyperbaric Medical Society. Indications for Hyperbaric Oxygen Therapy, 14th Edition. 2019. (UHMS 14th Edition)

6. Lipsky BA, et al. IWGDF/IDSA Guidelines on the Diagnosis and Treatment of Diabetic Foot Infections (2023 Update). Clin Infect Dis. 2023.

7. Wound Healing Society. Update on Guidelines for the Treatment of Chronic Wounds. Wound Rep Reg. 2022.

8. National Pressure Injury Advisory Panel (NPIAP). NPIAP Pressure Injury Staging System, 2016; updated 2019.

9. Veves A, et al. Graftskin, a human skin equivalent, is effective in the management of noninfected neuropathic diabetic foot ulcers: a prospective randomized multicenter clinical trial. Diabetes Care. 2001;24(2):290-295. (Apligraf pivotal trial)

10. Marston WA, et al. The efficacy and safety of Dermagraft in improving the healing of chronic diabetic foot ulcers: results of a prospective randomized trial. Diabetes Care. 2003;26(6):1701-1705. (Dermagraft pivotal trial)

11. Zelen CM, et al. A prospective randomised comparative parallel study of amniotic membrane wound graft in the management of diabetic foot ulcers. Int Wound J. 2013;10(5):502-507; and 2015 VLU study. (EpiFix RCTs)

12. American Diabetes Association. Standards of Care in Diabetes—2023. Diabetes Care. 2023;46(Suppl 1). Section on foot care and amputation prevention.